Kymab announces senior appointments
This article was originally published in Scrip
Executive Summary
Duncan Casson
Professor Ken Smith
Biopharmaceutical company Kymab, which develops monoclonal antibody drugs, has appointed three senior team members. Duncan Casson joins the firm as chief development officer. Prior to his appointment at Cambridge, UK-based Kymab, Mr Casson served as chief operating officer of PanGenetics. Professor Ken Smith joins Kymab as a member of its scientific advisory board. He is currently professor of medicine at the University of Cambridge and a consultant nephrologist and clinical immunologist. Additionally, Kymab has appointed Dr George Vassiliou senior clinical fellow, specializing in hematological cancer. Dr Vassiliou is a Wellcome Trust senior clinical fellow and heads the Hematological Cancer Genetics Group at the Wellcome Trust Sanger Institute.